ArticleCell & bioscience2026
5'-end uridine-derived base modification for siRNAs potency reinforcement.
Article in Cell & bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Small interfering RNAs (siRNAs), bound by Argonaute, efficiently cleave target mRNAs through full complementary base pairing, achieving potent gene silencing. While chemical modifications are widely employed to improve siRNA stability and binding affinity, modifying the 5'-end nucleotide of the guide strand remains a primary strategy for enhancing potency. In this study, we performed a structural analysis of the 5'-end binding pocket of the RISC complex to design a novel series of uridine-derived modifications and screen a library including 001U-018U and vs30U as candidates. We further tested the 001 ~ 003 μm-modified siRNA binding activity via in vitro RNA-induced silencing complex (RISC) loading in HepG2 cells and in vivo RISC loading in mice. These function valiation results indicated a significant improvement in gene silencing activity for the modified siRNAs compared to unmodified control. Additionally, preliminarily safety evaluations demonstrated the modified nucleoside carry no detectable cytotoxicity or genomic insertion risks. Our findings expand the chemical space of siRNA modification and provide new insights into the design of high-potency siRNA drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.